Enveric Biosciences Q2 2026 net loss $3.0M, cash $8.3M, EB-003 IND studies advance

Enveric Biosciences, Inc.

Net loss $3.0M ($0.76/share) vs $2.5M ($11.65/share) in Q2 2025; cash $8.3M at June 30, 2026.
Raised $5.0M gross from private placement plus $1.5M from warrant exercises during Q2.
Advanced EB-003 IND-enabling studies: genotoxicity initiated, non-hallucinogenic GloSensor data, no photoreactivity.
Secured U.S. Patent 12,605,361 for EVM301 series; received USPTO Notice of Allowance for EVM401 series.
Plans IND submission and Phase 1 trial for EB-003 in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.